CN116801899A - 通过肿瘤微环境重塑的溶瘤免疫疗法 - Google Patents
通过肿瘤微环境重塑的溶瘤免疫疗法 Download PDFInfo
- Publication number
- CN116801899A CN116801899A CN202180091007.7A CN202180091007A CN116801899A CN 116801899 A CN116801899 A CN 116801899A CN 202180091007 A CN202180091007 A CN 202180091007A CN 116801899 A CN116801899 A CN 116801899A
- Authority
- CN
- China
- Prior art keywords
- virus
- weeks
- pfu
- strain
- oncolytic virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116004P | 2020-11-19 | 2020-11-19 | |
| US63/116,004 | 2020-11-19 | ||
| PCT/US2021/059887 WO2022109133A1 (en) | 2020-11-19 | 2021-11-18 | Oncolytic immunotherapy by tumor micro-environment remodeling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116801899A true CN116801899A (zh) | 2023-09-22 |
Family
ID=81709792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180091007.7A Pending CN116801899A (zh) | 2020-11-19 | 2021-11-18 | 通过肿瘤微环境重塑的溶瘤免疫疗法 |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4604981A2 (en) * | 2022-10-19 | 2025-08-27 | KaliVir Immunotherapeutics, Inc. | Nucleic acids encoding soluble pd-1 and il-12 and uses thereof |
| CN115948411A (zh) * | 2022-11-23 | 2023-04-11 | 郑州大学 | 竞争性表达的il-12和il-23及其基因、重组载体和在制备治疗肿瘤药物中的应用 |
| CN115927471A (zh) * | 2022-11-23 | 2023-04-07 | 郑州大学 | A49r基因缺失的溶瘤痘苗病毒载体的构建方法及应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031681A1 (en) * | 1999-05-28 | 2003-02-13 | Mccart J. Andrea | Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2009054996A2 (en) * | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| WO2018058258A1 (en) * | 2016-09-30 | 2018-04-05 | University Health Network | Recombinant oncolytic viruses for cancer therapy |
| US20200140824A1 (en) * | 2018-11-06 | 2020-05-07 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| CN111556757A (zh) * | 2017-10-31 | 2020-08-18 | 西方溶瘤细胞有限公司 | 用于全身递送的平台溶瘤载体 |
| CN111655845A (zh) * | 2018-01-26 | 2020-09-11 | 联邦高等教育系统匹兹堡大学 | 代谢调节剂在肿瘤微环境中的表达以改善肿瘤的治疗 |
| US20200330596A1 (en) * | 2016-11-22 | 2020-10-22 | Alloplex Biotherapeutics, Inc. | Allogenic tumor cell vaccine |
| CN113454231A (zh) * | 2018-12-21 | 2021-09-28 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| IL71275A0 (en) * | 1983-03-21 | 1984-06-29 | Sparamedica Ag | Human interleukin-2-and its preparation |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993021173A1 (en) | 1992-04-17 | 1993-10-28 | Abbott Laboratories | Taxol derivatives |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| CA2309688C (en) | 1997-11-10 | 2007-04-24 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6198323B1 (en) | 1999-01-28 | 2001-03-06 | Lucent Technologies Inc. | Flip-flop having gated inverter feedback structure with embedded preset/clear logic |
| DE19929394A1 (de) | 1999-06-26 | 2000-12-28 | Schaeffler Waelzlager Ohg | Verfahren zur Ansteuerung einer Vorrichtung zum Variieren der Ventilsteuerzeiten einer Brennkraftmaschine, insbesondere einer Nockenwellen-Verstelleinrichtung mit hydraulisch entriegelbarer Startverriegelung |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
| DE60116075T4 (de) | 2000-04-25 | 2007-06-06 | Immunex Corp., Thousand Oaks | Behandlung von tumoren mit photodynamischer therapie |
| US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| WO2001091802A1 (en) | 2000-05-30 | 2001-12-06 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US7030099B2 (en) | 2000-07-21 | 2006-04-18 | Research Corporation Technologies, Inc. | Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells |
| AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1213025A1 (de) | 2000-12-06 | 2002-06-12 | Laboratoires Serobiologiques(Societe Anonyme) | Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa |
| EP1341817A2 (en) | 2000-12-08 | 2003-09-10 | Novo Nordisk A/S | Tff peptides |
| WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
| JP2003009883A (ja) | 2001-07-05 | 2003-01-14 | Mitsubishi Pharma Corp | マスト細胞の細胞死誘発剤 |
| AU2002350409A1 (en) | 2001-10-26 | 2003-05-06 | Uffe Holmskov | Surfactant protein-d and atherosclerosis |
| US7368122B1 (en) | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
| WO2004014314A2 (en) | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US20040143026A1 (en) | 2002-12-31 | 2004-07-22 | Shah Kishore R. | Bioadhesive hydrophilic composition for treatment of mammalian skin |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| MXPA05013879A (es) | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| AU2004272607B2 (en) | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| JP4719855B2 (ja) | 2003-12-05 | 2011-07-06 | 国立大学法人北海道大学 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| ES2433467T3 (es) | 2005-01-20 | 2013-12-11 | Isconova Ab | Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina |
| US20070029054A1 (en) | 2005-08-03 | 2007-02-08 | Nien Made Enterprise Co., Ltd. | Transverse cloth blind |
| US20100094560A1 (en) | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| WO2008023077A2 (en) | 2006-08-25 | 2008-02-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Compositions and methods for modulating an immune response |
| DK2402451T3 (en) * | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| GB0702695D0 (en) | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| EP2484691B1 (en) | 2007-07-10 | 2016-01-13 | Apogenix GmbH | TNF superfamily collectin fusion proteins |
| CN101970650B (zh) | 2008-03-06 | 2017-07-25 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| US10603351B2 (en) | 2008-08-21 | 2020-03-31 | Turnstone Limited Partnership | Engineered synergistic oncolytic viral symbiosis |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| CA2709292A1 (en) | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
| EP2617426B1 (en) | 2010-09-17 | 2016-08-10 | Japan Science and Technology Agency | Inhibitor of hmgb protein-mediated immune response activation |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| US9919047B2 (en) | 2011-01-04 | 2018-03-20 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| EP2527459A1 (en) | 2011-05-02 | 2012-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene detection of non-small cell lung cancer |
| KR102022952B1 (ko) | 2011-08-05 | 2019-09-20 | 신라젠(주) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9862932B2 (en) | 2012-07-24 | 2018-01-09 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| IN2015DN02335A (cg-RX-API-DMAC7.html) | 2012-09-28 | 2015-08-28 | Probiogen Ag | |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| KR20140122603A (ko) | 2013-04-10 | 2014-10-20 | 신라젠(주) | 세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포 |
| EP3461491B1 (en) | 2013-04-18 | 2024-11-13 | TILT Biotherapeutics Oy | Enhanced adoptive cell therapy |
| KR102322510B1 (ko) | 2013-07-18 | 2021-11-08 | 브이아이비 브이지더블유 | 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인 |
| ES2847305T3 (es) | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| US20160060313A1 (en) | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same |
| EP3186281B1 (en) | 2014-08-28 | 2019-04-10 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3217993A1 (en) | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| HK1255192A1 (zh) | 2015-09-08 | 2019-08-09 | Sillajen, Inc. | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US20180000733A1 (en) | 2016-06-30 | 2018-01-04 | Ava, Inc. | Safe and stable antiseptic solution comprising chlorhexidine |
| JP2019528753A (ja) | 2016-09-21 | 2019-10-17 | スティーブン エイチ. ソーン, | 高移動度グループboxi突然変異体 |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| AU2018223211B2 (en) | 2017-02-21 | 2025-02-27 | Adelaide university | T cells expressing chemokine receptors for treating cancer |
| US20200268831A1 (en) | 2017-09-15 | 2020-08-27 | The Texas A&M University System | Methods for enhancing immunotherapy in the treatment of cancer |
| CA3099330A1 (en) | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
| WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| US11529402B2 (en) | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11685904B2 (en) | 2019-02-14 | 2023-06-27 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3155090A1 (en) | 2019-09-20 | 2021-03-25 | Transgene | Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody |
| BR112022011158A2 (pt) | 2019-12-12 | 2022-08-30 | Ignite Immunotherapy Inc | Vírus vaccinia oncolítico variante e métodos de uso do mesmo |
| MX2022008547A (es) | 2020-01-09 | 2022-08-10 | Pfizer | Virus de vacuna recombinante. |
| MX2023000734A (es) | 2020-07-14 | 2023-02-13 | Pfizer | Virus vaccinia recombinante. |
-
2021
- 2021-11-18 JP JP2023529962A patent/JP2023552289A/ja active Pending
- 2021-11-18 WO PCT/US2021/059887 patent/WO2022109133A1/en not_active Ceased
- 2021-11-18 AU AU2021385059A patent/AU2021385059A1/en not_active Abandoned
- 2021-11-18 IL IL302897A patent/IL302897A/en unknown
- 2021-11-18 TW TW110143069A patent/TW202227621A/zh unknown
- 2021-11-18 KR KR1020237019985A patent/KR20230110545A/ko active Pending
- 2021-11-18 CR CR20230268A patent/CR20230268A/es unknown
- 2021-11-18 EP EP21895584.7A patent/EP4247410A4/en active Pending
- 2021-11-18 MX MX2023005853A patent/MX2023005853A/es unknown
- 2021-11-18 CN CN202180091007.7A patent/CN116801899A/zh active Pending
- 2021-11-18 CA CA3197371A patent/CA3197371A1/en active Pending
- 2021-11-18 PE PE2023001681A patent/PE20231175A1/es unknown
-
2023
- 2023-02-03 US US18/105,374 patent/US12403165B2/en active Active
- 2023-05-08 JO JOJO/P/2023/0104A patent/JOP20230104A1/ar unknown
- 2023-05-17 CO CONC2023/0006544A patent/CO2023006544A2/es unknown
- 2023-05-17 DO DO2023000098A patent/DOP2023000098A/es unknown
- 2023-05-19 CL CL2023001450A patent/CL2023001450A1/es unknown
- 2023-06-19 EC ECSENADI202345508A patent/ECSP23045508A/es unknown
-
2024
- 2024-09-23 US US18/892,948 patent/US20250041368A1/en active Pending
- 2024-09-23 US US18/892,953 patent/US20250009824A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031681A1 (en) * | 1999-05-28 | 2003-02-13 | Mccart J. Andrea | Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2009054996A2 (en) * | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| WO2018058258A1 (en) * | 2016-09-30 | 2018-04-05 | University Health Network | Recombinant oncolytic viruses for cancer therapy |
| US20200330596A1 (en) * | 2016-11-22 | 2020-10-22 | Alloplex Biotherapeutics, Inc. | Allogenic tumor cell vaccine |
| CN111556757A (zh) * | 2017-10-31 | 2020-08-18 | 西方溶瘤细胞有限公司 | 用于全身递送的平台溶瘤载体 |
| CN111655845A (zh) * | 2018-01-26 | 2020-09-11 | 联邦高等教育系统匹兹堡大学 | 代谢调节剂在肿瘤微环境中的表达以改善肿瘤的治疗 |
| US20200140824A1 (en) * | 2018-11-06 | 2020-05-07 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| CN113454231A (zh) * | 2018-12-21 | 2021-09-28 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250009824A1 (en) | 2025-01-09 |
| AU2021385059A9 (en) | 2024-10-24 |
| CA3197371A1 (en) | 2022-05-27 |
| CR20230268A (es) | 2023-07-26 |
| TW202227621A (zh) | 2022-07-16 |
| US12403165B2 (en) | 2025-09-02 |
| MX2023005853A (es) | 2023-06-02 |
| JP2023552289A (ja) | 2023-12-15 |
| WO2022109133A1 (en) | 2022-05-27 |
| PE20231175A1 (es) | 2023-08-01 |
| CL2023001450A1 (es) | 2023-10-20 |
| JOP20230104A1 (ar) | 2023-05-08 |
| AU2021385059A1 (en) | 2023-06-08 |
| EP4247410A4 (en) | 2025-05-07 |
| KR20230110545A (ko) | 2023-07-24 |
| DOP2023000098A (es) | 2023-08-15 |
| ECSP23045508A (es) | 2023-07-31 |
| IL302897A (en) | 2023-07-01 |
| CO2023006544A2 (es) | 2023-05-19 |
| US20250041368A1 (en) | 2025-02-06 |
| US20230256041A1 (en) | 2023-08-17 |
| EP4247410A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12403165B2 (en) | Oncolytic immunotherapy by tumor micro-environment remodeling | |
| RU2583295C2 (ru) | Нуклеиновая кислота, содержащая или кодирующая гистоновую структуру типа "стебель-петля" и поли(а)-последовательность или сигнал полиаденилирования, для повышения экспрессии кодируемого белка | |
| US12036257B2 (en) | Platform oncolytic vector for systemic delivery | |
| US20190134174A1 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| US12247214B2 (en) | Vaccinia viral vectors encoding chimeric virus like particles | |
| JP2020530437A (ja) | 個別化ワクチン | |
| WO1999046278A1 (en) | Viral vector directed to predetermined target cells | |
| US10344067B2 (en) | RNA viruses expressing IL-12 for immunovirotherapy | |
| US20210017541A1 (en) | Recombinant viral vector and uses thereof | |
| TW202305125A (zh) | 用於經修飾mhc表現之溶瘤病毒 | |
| AU2019208892B2 (en) | Recombinant vaccinia virus and pharmaceutical composition comprising same | |
| WO2023020556A1 (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| CN116159131B (zh) | Trim21及其促进剂在制备抗肿瘤生物治疗药物中的应用 | |
| HK40097820A (en) | Oncolytic immunotherapy by tumor micro-environment remodeling | |
| EA049375B1 (ru) | Онколитическая иммунотерапия путем ремоделирования микроокружения опухоли | |
| US12115190B2 (en) | IRF-4 engineered T cells and uses thereof in treating cancer | |
| CN116724110A (zh) | 重组溶瘤病毒及其构建方法和用途 | |
| EP4029515A1 (en) | Anti-infection effects of hnrnpa2b1 and use thereof | |
| US20250115928A1 (en) | Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer Treatment | |
| US12194057B2 (en) | NXTAR-derived oligonucleotides and uses thereof | |
| WO2014017941A1 (ru) | Многопрофильный промотор и его использование в генной терапии рака | |
| JP2020530485A (ja) | 医薬キット及びその使用法 | |
| HK40122972A (en) | Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof | |
| JP2025536947A (ja) | Tgf-ベータ阻害剤およびil-12をコードする核酸ならびにその使用 | |
| WO2024245445A1 (zh) | Malt1肿瘤抑制剂、含有其的药物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40097820 Country of ref document: HK |
|
| CB03 | Change of inventor or designer information |
Inventor after: Stephen Howard Thorne Inventor after: Zhang Mingrui Inventor after: Daniel. J. Byrd Inventor before: Stephen Howard Thorne Inventor before: Zhang Mingrui Inventor before: Daniel. J. Byrd |
|
| CB03 | Change of inventor or designer information |